Fotocitizen / Pixabay

Rare Community Profiles: Dr. Pisit “Duke” Pitukcheewanont Discusses Phase 2 Results in LUM-201 for Pediatric Growth Hormone Deficiency

• Post author:Jessica Lynn
• Post published:February 6, 2024
• Post category:Growth hormone deficiency/Pediatric Growth Hormone Deficiency (GHD)

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Dr. Pisit “Duke” Pitukcheewanont Discusses Phase 2 Results in LUM-201 for Pediatric Growth Hormone Deficiency

source: pixabay.com

Sogroya Now Approved for Pediatric Growth Hormone Deficiency (GHD)

• Post author:Jessica Lynn
• Post published:May 3, 2023
• Post category:Pediatric Growth Hormone Deficiency (GHD)

  In July 2022, Patient Worthy reported on data from the Phase 3 REAL 4 clinical trial. During the trial, researchers compared the safety, efficacy, and tolerability of Sogroya (somapacitan-beco)…

Continue Reading Sogroya Now Approved for Pediatric Growth Hormone Deficiency (GHD)

source: unsplash.com

ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency

• Post author:Jessica Lynn
• Post published:July 6, 2022
• Post category:Growth hormone deficiency/Pediatric Growth Hormone Deficiency (GHD)

  The ENDO 2022 Annual Congress took place from June 11-14, 2022. During the Congress, stakeholders met to discuss care, treatments, and research within endocrinology. In a news release from…

Continue Reading ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency

source: pixabay.com

New Once a Week Therapy For Growth Hormone Deficiency is FDA Approved

• Post author:Trudy Horsting
• Post published:September 24, 2021
• Post category:Growth hormone deficiency

The FDA has recently approved Skytrofa as a treatment for children at least one year of age who are facing growth failure as a result of an inadequate secretion of…

Continue Reading New Once a Week Therapy For Growth Hormone Deficiency is FDA Approved

Phase 3 Trial for Pediatric Growth Hormone Deficiency in China Completed Enrollment On Time Despite COVID-19 Setback

• Post author:Trudy Horsting
• Post published:April 27, 2021
• Post category:Pediatric Growth Hormone Deficiency (GHD)

VISEN Pharmaceuticals has recently announced that enrollment has been completed for their Phase 3 clinical trial examining the safety and efficacy of TransCon hGH compared to daily rhGH in patients…

Continue Reading Phase 3 Trial for Pediatric Growth Hormone Deficiency in China Completed Enrollment On Time Despite COVID-19 Setback